Idexx Laboratories, Inc [IDXX] stock is trading at $689.35, down -1.11%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IDXX shares have lost -1.73% over the last week, with a monthly amount glided 8.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Idexx Laboratories, Inc [NASDAQ: IDXX] stock has seen the most recent analyst activity on October 31, 2025, when Stifel upgraded its rating to a Buy but kept the price target unchanged to $700 for it. Previously, UBS started tracking the stock with Neutral rating on October 01, 2025, and set its price target to $720. On August 05, 2025, BTIG Research reiterated its Buy rating and revised its price target to $785 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $625 on July 01, 2025. Leerink Partners initiated its recommendation with a Outperform and recommended $500 as its price target on December 02, 2024. BTIG Research started tracking with a Buy rating for this stock on July 25, 2024, and assigned it a price target of $580. In a note dated January 30, 2024, Piper Sandler downgraded a Neutral rating on this stock but restated the target price of $525.
Idexx Laboratories, Inc [IDXX] stock has fluctuated between $356.14 and $735.00 over the past year. Currently, Wall Street analysts expect the stock to reach $795.83 within the next 12 months. Idexx Laboratories, Inc [NASDAQ: IDXX] shares were valued at $689.35 at the most recent close of the market. An investor can expect a potential return of 15.45% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
Idexx Laboratories, Inc [NASDAQ:IDXX] reported sales of 4.17B for the trailing twelve months, which represents a growth of 13.29%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.3, Equity is 0.68 and Total Capital is 0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 681.65 points at the first support level, and at 673.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 703.89, and for the 2nd resistance point, it is at 718.42.
Ratios To Look Out For
For context, Idexx Laboratories, Inc’s Current Ratio is 1.12. Also, the Quick Ratio is 0.81, while the Cash Ratio stands at 0.17. Considering the valuation of this stock, the price to sales ratio is 13.21, the price to book ratio is 35.32 and price to earnings (TTM) ratio is 54.65.
Transactions by insiders
Recent insider trading involved Hunt Nimrata, Executive Vice President, that happened on Nov 07 ’25 when 9425.0 shares were sold. Officer, NIMRATA K HUNT completed a deal on Nov 07 ’25 to buy 9425.0 shares. Meanwhile, Director SZOSTAK M ANNE sold 2187.0 shares on Aug 22 ’25.
